This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Press ReleasesIn the MediaAwardsScientific PublicationsRelated LinksSubscription Press MailingMedia Contact

Press Archive

Archive

Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for…

Read more

ITM announced today the appointment of Mona M Wahba, MD, MSM to the position of Deputy Chief Medical Officer.

Read more

Conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy (TRT) in South Korea.

Read more

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma…

Read more

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized…

Read more

Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617

Read more